Form 4: RAPT Therapeutics Director, Mary Ann Gray, Acquires 36,490 Stock Options

Mary Ann Gray, a director of RAPT Therapeutics, acquired 36,490 stock options on May 22, 2024, exercisable for common stock.

Summary

• This document is a Form 4 filing with the SEC, reporting a change in beneficial ownership for Mary Ann Gray, a director of RAPT Therapeutics, Inc.
• On May 22, 2024, Ms. Gray acquired 36,490 stock options with an exercise price of $4.63.
• The options vest in 12 equal monthly installments from the grant date and expire on May 21, 2034.
• Following the transaction, Ms. Gray directly owns 36,490 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of options by a director is mildly positive, suggesting confidence, but not definitively so.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of stock options by a director may have a slightly positive impact on shareholder sentiment.

Key Dates